Tissue and Serum Level of NLRP1, NLRP3 and Il-18 in Early Stages of mf Patients

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

May 15, 2024

Study Completion Date

May 30, 2024

Conditions

Early Disease Onset

Interventions

DEVICE

Puva (psoralin and uva )

Intervention will be given for 48 sessions or till coplete resolution of biopsied plaque

All Listed Sponsors

lead

Cairo University

OTHER

NCT06066554 - Tissue and Serum Level of NLRP1, NLRP3 and Il-18 in Early Stages of mf Patients | Biotech Hunter | Biotech Hunter